PTC Therapeutics PTCT Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's operating lease right-of-use asset amortization?
- PTC Therapeutics (PTCT) reported operating lease right-of-use asset amortization of $1.76M in Q1 2026.
- How has PTC Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- PTC Therapeutics's operating lease right-of-use asset amortization decreased by 1.6% year-over-year, from $1.79M to $1.76M.
- What is the long-term trend for PTC Therapeutics's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), PTC Therapeutics's operating lease right-of-use asset amortization has grown at a 0.3% compound annual growth rate (CAGR), from $7.39M to $7.47M.